Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial
about
PINP as a biological response marker during teriparatide treatment for osteoporosisPrevention and treatment of bone changes associated with exposure to glucocorticoidsLong-term safety of antiresorptive treatment: bone material, matrix and mineralization aspectsManagement of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk.Advanced CT based in vivo methods for the assessment of bone density, structure, and strength.Prevention of glucocorticoid induced bone changes with beta-ecdysone.Bisphosphonates and glucocorticoid-induced osteoporosis: cons.More than 6 Months of Teriparatide Treatment Was More Effective for Bone Union than Shorter Treatment Following Lumbar Posterolateral Fusion Surgery.Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis.Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates.Accuracy of finite element analyses of CT scans in predictions of vertebral failure patterns under axial compression and anterior flexionSclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapyEarly changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosisVery high frequency of fragility fractures associated with high-dose glucocorticoids in postmenopausal women: A retrospective study.Review of new guidelines for the management of glucocorticoid induced osteoporosis.The effect of zoledronic acid on the fracture risk in men with osteoporosis.Safety issues and adverse reactions with osteoporosis management.Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.Finite Element Analysis of Denosumab Treatment Effects on Vertebral Strength in Ovariectomized Cynomolgus Monkeys.[Male osteoporosis].Bone Tissue Properties Measurement by Reference Point Indentation in Glucocorticoid-Induced Osteoporosis.Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines.Romosozumab: from basic to clinical aspects.Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment.Short-term daily teriparatide in patients with rheumatoid arthritis.Glucocorticoids, Inflammation and Bone.Glucocorticoid-Induced Osteoporosis.Glucocorticoid-induced Osteoporosis.
P2860
Q26859267-E91CCE10-021D-498E-AF3E-C0E3E938EF7FQ26861474-8227EA37-9AB0-454B-80BB-6123F45FE975Q27025945-569DF696-16AC-423A-9772-E1E0110AC56FQ30946308-8AF126AD-C00F-4843-8529-D7A752896921Q34742707-9D5B4F07-6977-454D-A32D-B4750008A854Q35163490-81FB66B5-70F5-409A-9CE8-A4D40A5ED6A2Q35882427-4932C255-5E28-4CA3-A839-B0A08034920FQ35909167-469084C0-494F-4F89-A23C-AA28BAE202B5Q36873339-4CD978D0-0233-41DE-AAFC-2D6EB262D6A4Q37083734-218C2DB4-51EC-4946-9399-27D124AECF06Q37113984-CA61CEE7-0050-40B8-A48F-31C63E14883EQ37119856-EBEE122F-776D-4FDF-80DB-1007B42A9590Q37251693-5F870F18-29C4-4547-A803-0A088BF07756Q37337557-69C48741-0083-42D5-9E3B-CD3F409497E0Q37720586-86935BB5-1BD9-4922-9081-896B03A6F54EQ38151513-FD020757-B0BC-4F43-870B-632F7C2C9457Q38182950-2F65C123-6429-41E2-8E21-90EA8C6FEA36Q38677822-C44060C1-05A2-45EB-B4F0-E6783220E527Q38702184-34FDAFC7-2FAA-4506-B8B1-CFA69887E0F0Q39183207-B8A70D34-9D26-4C98-9A17-451C7D8C2FE0Q39791628-EDF46BAD-DB46-4B1C-A106-B0CF3940B9DEQ40780710-8FF94E2B-CC62-430F-AEC0-FF1181030025Q43509107-C0AB283B-E9FE-438B-9170-300AA6615805Q45045554-F84AA1F8-A29D-4B98-AE0F-D94EF492E36DQ45424127-233A45B4-51D1-41C7-8412-9FDB3713358CQ48368605-7B2E36B0-3062-484F-9BC0-2A7D9C72598EQ48694023-9BAAAF7E-1893-4C6B-B621-A9D8B342C403Q50128187-3BA30549-17DB-4630-809F-4AD599F0121CQ51093091-89387C08-A821-4FE3-87C6-E48A1849BEE7Q55383510-AD6627EC-A512-4BF0-A274-0B419DD2473D
P2860
Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparative effects of teripar ...... results of the EuroGIOPs trial
@en
Comparative effects of teripar ...... esults of the EuroGIOPs trial.
@nl
type
label
Comparative effects of teripar ...... results of the EuroGIOPs trial
@en
Comparative effects of teripar ...... esults of the EuroGIOPs trial.
@nl
prefLabel
Comparative effects of teripar ...... results of the EuroGIOPs trial
@en
Comparative effects of teripar ...... esults of the EuroGIOPs trial.
@nl
P2093
P2860
P356
P1476
Comparative effects of teripar ...... results of the EuroGIOPs trial
@en
P2093
Andreas Reisinger
Beatriz Sanz
Christian Graeff
Christopher Niedhart
Claus-C Glüer
Emilio Martín-Mola
Federico Hawkins
Fernando Marin
Friederike Thomasius
Georgios Kapetanos
P2860
P304
P356
10.1002/JBMR.1870
P577
2013-06-01T00:00:00Z